Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

Rhea-AI Summary

Esperion (NASDAQ: ESPR) announced two moderated poster presentations from the CLEAR Outcomes trial at the American College of Cardiology 2026 Annual Scientific Session (ACC.26), March 28-30 in New Orleans.

Both analyses evaluate bempedoic acid in underrepresented populations: stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases.

News Market Reaction – ESPR

+0.74%

1 alert

+0.74% News Effect

On the day this news was published, ESPR gained 0.74%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 28–30, 2026 Stroke analysis session: Session 1069 Autoimmune CV session: Session 1084 +5 more

8 metrics

Conference dates March 28–30, 2026 ACC.26 Annual Scientific Session timing

Stroke analysis session Session 1069 Bempedoic acid and stroke in statin-intolerant patients

Autoimmune CV session Session 1084 Bempedoic acid in autoimmune or inflammatory disease patients

Stroke poster time 4:18–4:25 pm ET March 28, 2026 moderated poster presentation

Autoimmune poster time 9:30–9:37 am ET March 29, 2026 moderated poster presentation

Global approvals More than 40 countries Approvals for Esperion’s oral, once-daily non-statin therapies

Price move 10.25% Share price change prior to ACC.26 news

52-week range $0.6925–$4.175 Pre-news 52-week low and high for ESPR

Market Reality Check

Price: $2.50 Vol: Volume 5,816,021 is 18% a...

normal vol

$2.50 Last Close

Volume Volume 5,816,021 is 18% above the 20-day average of 4,918,671. normal

Technical Trading above 200-day MA at $2.59, with price at $2.69 pre-announcement.

Peers on Argus

ESPR was up 10.25% while key peers showed mixed, smaller moves (e.g., AQST +3.72...

1 Down

ESPR was up 10.25% while key peers showed mixed, smaller moves (e.g., AQST +3.72%, SIGA +2.25%, ORGO -2.27%). Momentum scanner only flagged EBS moving down, supporting a company-specific reaction rather than a coordinated sector move.

Previous Clinical trial Reports

5 past events · Latest: Oct 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 16	Preclinical nomination	Positive	+5.2%	Nominated ESP-2001 for PSC with plans for IND-enabling studies.
Oct 03	Patent settlement	Positive	+13.8%	Settlement with Dr. Reddy’s limiting generic entry before April 2040.
Aug 29	Guideline upgrade	Positive	+0.5%	Level 1a ESC/EAS guideline recommendation for bempedoic acid.
Mar 20	Phase 3 alignment	Positive	-3.0%	FDA alignment to initiate pediatric Phase 3 trials in familial hypercholesterolemia.
May 20	Phase 3 success	Positive	+5.1%	Japan Phase 3 trial met primary endpoint with significant LDL-C reduction.

Pattern Detected

Clinical and guideline-related updates have typically produced modestly positive moves, with an average same-tag reaction of 4.3% and only one notable negative response.

Recent Company History

Over the past two years, ESPR’s clinical and guideline-related news has highlighted expanding use of bempedoic acid, from a successful Phase 3 trial in Japan (May 20, 2024) to FDA alignment on pediatric Phase 3 trials (Mar 20, 2025). Positive European and U.S. guideline endorsements and IP-protective settlements further strengthened the franchise. Today’s CLEAR Outcomes subgroup analyses at ACC.26 extend this pattern of leveraging existing data into new patient populations.

Historical Comparison

+4.3% avg move · In the last five clinical-trial-tagged events, ESPR moved on average ±4.3%. Today’s 10.25% gain on n...

clinical trial

+4.3%

Average Historical Move clinical trial

In the last five clinical-trial-tagged events, ESPR moved on average ±4.3%. Today’s 10.25% gain on new CLEAR Outcomes analyses represents a stronger-than-usual reaction for this news type.

Clinical news has evolved from Phase 3 LDL-C results and global guideline endorsements to pediatric development and new indications like PSC; the ACC.26 CLEAR Outcomes subgroup analyses extend this trajectory into additional high-risk patient populations.

Market Pulse Summary

This announcement highlights two moderated poster presentations from the CLEAR Outcomes trial, focus...

Analysis

This announcement highlights two moderated poster presentations from the CLEAR Outcomes trial, focusing on stroke incidence in statin-intolerant patients and cardiovascular outcomes in autoimmune or inflammatory diseases at ACC.26 (March 28–30, 2026). It reinforces Esperion’s strategy around bempedoic acid and ACLY biology across diverse patient populations. In context of prior positive guideline endorsements and advancing programs, investors may watch for how these subgroup data support future label expansions and real-world uptake.

Key Terms

bempedoic acid, clear outcomes, statins, cardiometabolic, +4 more

8 terms

bempedoic acid medical

"Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations"

Bempedoic acid is an oral medicine that helps lower LDL cholesterol by blocking a key step in the liver’s cholesterol production pathway; think of it as turning off a factory machine upstream so less product reaches the shelves. It matters to investors because regulatory approvals, clinical results, pricing, patent life and how widely doctors adopt the drug affect future sales and a company’s revenue prospects, similar to how a new popular product can change a firm’s market value.

clear outcomes medical

"new insights from the CLEAR Outcomes trial among an audience"

Clear outcomes are specific, measurable results or end points that leave little doubt about whether an initiative — such as a clinical trial, product launch, or strategic program — succeeded or failed. They matter to investors because well-defined outcomes reduce uncertainty and make it easier to compare risks and rewards, like having a clearly marked finish line that tells you if the project reached its goal and how to value the company going forward.

statins medical

"need of Alternatives to Statins in Cardiovascular Risk Management"

Statins are a widely used class of prescription drugs that lower levels of cholesterol in the blood by blocking the biochemical step the body uses to make cholesterol; think of them as a filter that reduces material that can build up inside arteries. They matter to investors because prescribing rates, patent status, safety concerns, and regulatory approvals or label changes directly affect drug makers' sales, healthcare costs, and the outlook for companies that develop, manufacture, or compete with cholesterol-lowering therapies.

cardiometabolic medical

"developing and delivering innovative cardiometabolic and rare/orphan disease therapies"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

orphan disease medical

"innovative cardiometabolic and rare/orphan disease therapies"

A rare medical condition that affects a very small number of people, often so few that standard drug development and commercial sales are impractical. For investors it matters because treatments for these conditions can qualify for special regulatory incentives, faster approval paths and price premiums, so a successful therapy is like owning a product that dominates a tiny but underserved niche market — high potential reward but also higher scientific and commercial risk.

acly biology medical

"The Company leverages deep domain expertise in ACLY biology"

ACLY biology concerns the role of the enzyme ATP citrate lyase (ACLY) in converting cell fuel into acetyl units used to build fats and modify proteins, essentially acting like a factory machine that turns raw energy into construction materials for cells. Investors care because ACLY is a common drug target for conditions such as metabolic disease, fatty liver and some cancers; changes in ACLY-related research or therapies can affect the value of companies developing treatments or diagnostics.

ldl-c medical

"maintain their low-density lipoprotein cholesterol (LDL-C) levels"

LDL-C stands for low-density lipoprotein cholesterol, the portion of cholesterol carried in the blood by LDL particles that is commonly linked to buildup of plaque in arteries—think of it like sticky debris that can clog pipes. Investors care because changes in LDL-C are a key measure used by regulators and clinicians to judge the effectiveness of cardiovascular drugs and devices, shape insurance coverage, and influence market demand for treatments that lower heart attack and stroke risk.

primary sclerosing cholangitis medical

"including treatments for Primary Sclerosing Cholangitis and renal diseases"

A chronic disease in which the tubes that carry bile from the liver become inflamed and scarred, gradually blocking flow and potentially causing liver damage or failure; think of it like corrosion and narrowing in the body’s plumbing that disrupts normal cleanup and digestion. It matters to investors because there is no widely effective cure, so diagnostic advances, drugs, or procedures that slow progression can create meaningful commercial markets and clinical trial, regulatory and pricing risks that affect valuations in healthcare and biotech companies.

AI-generated analysis. Not financial advice.

Reviews Bempedoic Acid as Therapeutic Option for Diverse Patient Populations in Need of Alternatives to Statins in Cardiovascular Risk Management

ANN ARBOR, Mich., March 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that two abstracts have been accepted for presentation in moderated poster sessions at the upcoming American College of Cardiology’s 2026 Annual Scientific Session (ACC.26) taking place March 28-30, 2026 in New Orleans, LA.

“ACC.26 provides an important platform to share new insights from the CLEAR Outcomes trial among an audience of the world’s leading cardiologists,” said Sheldon Koenig, Chief Executive Officer of Esperion. “These analyses deepen our understanding of cardiovascular risk reduction in patients with other co-morbidities who are often underrepresented in traditional studies and reinforce our mission to deliver meaningful therapeutic options for diverse patient populations who need alternatives to statins.”

Moderated Presentations
Title: Session: Location: Date & Time: Authors: Presenter:	Bempedoic Acid and Incidence of Stroke Among Statin-Intolerant Patients: An Analysis of The Clear Outcomes Trial 1069 Moderated Poster Theatre 06, Posters, Hall E Saturday, March 28, 2026, 4:18 – 4:25 pm ET C. Pires Zingano, D. Brennan, M. Li, W. Sasiela, L. Bloedon, S.E. Nissen, L.J. Laffin Carolina Pires Zingano, MD (Cleveland Clinic)
Title: Session: Location: Date & Time: Authors: Presenter:	Bempedoic Acid and Cardiovascular Outcomes in Patients with Autoimmune or Inflammatory Diseases: An Analysis of the Clear Outcomes Trial 1084 Moderated Poster Theater 05, Posters, Hall E Sunday, March 29, 2026, 9:30 – 9:37 am ET B. Frison Spiazzi, B. Weber, D. Brennan, L. Bloedon, M. Li, S.E. Nissen, L.J. Laffin Bernardo Frison Spiazzi, MD (Cleveland Clinic)

Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com and follow Esperion on LinkedIn and X.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

FAQ

What will Esperion (ESPR) present at ACC.26 on March 28-30, 2026?

Esperion will present two moderated poster analyses from CLEAR Outcomes focusing on bempedoic acid in special populations. According to the company, sessions examine stroke incidence in statin-intolerant patients and cardiovascular outcomes in autoimmune or inflammatory disease patients, with named presenters and scheduled times.

When and where is the Esperion (ESPR) poster on stroke incidence presented at ACC.26?

The stroke incidence poster is scheduled for March 28, 2026, at 4:18–4:25 pm ET in Hall E. According to the company, Carolina Pires Zingano, MD (Cleveland Clinic) is listed as the presenter for the moderated poster theatre session.

What is the focus of the Esperion (ESPR) CLEAR Outcomes analysis for autoimmune or inflammatory disease patients?

The analysis evaluates cardiovascular outcomes with bempedoic acid in patients with autoimmune or inflammatory diseases. According to the company, the moderated poster will present data at ACC.26 on March 29, 2026, with Bernardo Frison Spiazzi, MD listed as presenter.

How do these CLEAR Outcomes presentations affect Esperion's position on non-statin therapies (ESPR)?

The presentations aim to deepen evidence for bempedoic acid in populations needing statin alternatives. According to the company, the analyses reinforce Esperion’s mission to offer therapeutic options for diverse, underrepresented cardiovascular-risk populations.

Where can investors find more information about Esperion (ESPR) and the ACC.26 presentations?

Investors can review Esperion’s investor contact details and company information for follow-up and materials. According to the company, investor relations and media contacts are provided for inquiries and further details on the presentations and data.